Full-Time

Senior Software Engineer

Full Stack

Updated on 3/14/2025

Veeva Systems

Veeva Systems

5,001-10,000 employees

Quality and regulatory software solutions provider

Compensation Overview

$110k - $270kAnnually

+ Variable Bonus + Stock Bonus

Senior

No H1B Sponsorship

Remote in USA

Applicants must have the unrestricted right to work in the United States. Veeva will not provide sponsorship at this time.

Category
Full-Stack Engineering
Software Engineering
Required Skills
JavaScript
React.js
MySQL
Java
RDBMS
Oracle
HTML/CSS
Requirements
  • 5+ years of experience in software product development
  • Experience with JavaScript and React; Experience with backend development in Java
  • Experience with CSS abstraction layers (e.g. SASS or JSS)
  • Experience with RDBMS such as MySQL, Oracle, or MS SQL Server
  • Strong communication skills
  • BS in engineering/computer science or equivalent
  • We are looking for strong mentors with a proven record of making your team better
  • Applicants must have the unrestricted right to work in the United States. Veeva will not provide sponsorship at this time
Responsibilities
  • Participate in all aspects of the SDLC
  • Collaborate with Product Managers, other Engineers, and domain experts to design and develop cutting-edge applications in life science
  • Collaborate with Quality Assurance Engineers to ensure accurate and comprehensive testing coverage
  • Contribute to troubleshooting and technical support of the product
Desired Qualifications
  • Previous experience working in an agile environment
  • Experience with the Spring framework
  • Experience with ES6
  • Experience with Software-as-a-Service (SaaS) product development
  • Experience with content management products and technologies

Veeva Systems offers software solutions for quality, regulatory, and advertising claims management, focusing on consumer products and chemical companies. Their cloud-based platform provides visibility and traceability throughout the product journey, ensuring compliance with regulations and enhancing product quality. Unlike competitors, Veeva has specialized expertise in heavily regulated industries, having expanded from Life Sciences to Chemical and Consumer Goods. The company's goal is to help clients bring safe and compliant products to market more efficiently.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

2007

Simplify Jobs

Simplify's Take

What believers are saying

  • Veeva's expansion into chemical and consumer goods markets meets growing compliance demands.
  • AI integration enhances Veeva's predictive analytics capabilities for better decision-making.
  • Veeva's subscription model aligns with the SaaS adoption trend in life sciences.

What critics are saying

  • Emerging cloud-based software providers could erode Veeva's market share.
  • Rapid technological advancements may strain Veeva's resources and profitability.
  • Data privacy concerns and regulatory scrutiny could affect Veeva's operations.

What makes Veeva Systems unique

  • Veeva Systems specializes in cloud-based software for the life sciences industry.
  • The company offers end-to-end visibility and traceability in product journeys.
  • Veeva's subscription model ensures continuous updates and improvements for clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Parental leave

PTO

Free food

Health, dental, & vision insurance

Gym membership reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

0%
Simply Wall St
Mar 13th, 2025
Veeva Systems (NYSE:VEEV) Announces Tina Hunt's Retirement From Board Before 2025 Shareholders Meeting

Veeva Systems (NYSE:VEEV) announces Tina Hunt's retirement from board before 2025 shareholders meeting.

PR Newswire
Mar 11th, 2025
Boehringer Ingelheim Partners With Veeva To Launch 'One Medicine Platform'

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesINGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases."Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. "Veeva Development Cloud provides the technology foundation for Boehringer's One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.""By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals," said Rik van Mol, senior vice president, Veeva Development Cloud. "This is an exciting milestone toward realizing Veeva and Boehringer's shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes."Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health

PharmiWeb
Mar 11th, 2025
Boehringer Ingelheim Partners With Veeva To Launch ‘One Medicine Platform’

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesLondon, UK — 11 March 2025 — ​​​Today, ​Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud​.​​ They ​first announced the One Medicine collaboration in March 2022.​ ​The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development.With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimise trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.“Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world,” said Oliver Fink, head of learning, process and digitalisation at Boehringer Ingelheim. “Veeva Development Cloud provides the technology foundation for Boehringer’s One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.”“By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals,” said Rik van Mol, senior vice president, Veeva Development Cloud. “This is an exciting milestone toward realising Veeva and Boehringer’s shared mission to advance the use of data and technology to modernise clinical trials and deliver better patient outcomes.”Veeva Development Cloud is the technology foundation for product development​,​ bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain

Data Centre Magazine
Mar 11th, 2025
Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform'

INGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ - Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud.

Investing.com
Mar 6th, 2025
Citi maintains Veeva stock Buy rating, $307 target post Q4 beat

Additionally, Veeva Systems secured its fourth top 20 customer in the Safety category and witnessed a top 20 customer commit comprehensively to its clinical solutions.